A $220 million funding round will help advance a potential new treatment for patients with multiple myeloma.
Ropes & Gray advised Pfizer in connection with its participation in CellCentric’s oversubscribed Series D financing to support the continued development of inobrodib, a first-in-class oral p300/CBP inhibitor now in registration-enabling clinical trials for relapsed/refractory multiple myeloma.
The transaction builds on Ropes & Gray’s work advising Pfizer on its 2023 strategic investment in CellCentric.
The team was led by Bradford Flint, David Dowling, Velyana Borisova, and Iain Fox, with support from David Saltzman and Lisa 文琳 Kaltenbrunner.
#multiplemyeloma #cancertreatment #Pfizerfunding #clinicaltrials #healthcareinnovation
Ropes & Gray advised Pfizer in connection with its participation in CellCentric’s oversubscribed Series D financing to support the continued development of inobrodib, a first-in-class oral p300/CBP inhibitor now in registration-enabling clinical trials for relapsed/refractory multiple myeloma.
The transaction builds on Ropes & Gray’s work advising Pfizer on its 2023 strategic investment in CellCentric.
The team was led by Bradford Flint, David Dowling, Velyana Borisova, and Iain Fox, with support from David Saltzman and Lisa 文琳 Kaltenbrunner.
#multiplemyeloma #cancertreatment #Pfizerfunding #clinicaltrials #healthcareinnovation
Shared byAvery Park - 12 days ago
Log in to comment
Loading ..
Related Articles
Strategic Financing Collaboration Supports Development of Atopic Dermatitis Treatment
Europe's Data Center Market Booms with €1.2B Financing for AtlasEdge
Arca Space Capital Acquires Rogelfrut to Build a Leading Artisanal Gelato Platform
Unlocking Chronoleadership: How Biological Rhythms Enhance Workplace Culture
DOJ Accelerates Enforcement for Benefits Fraud Qui Tam Cases
Collaboration Key to Rare Disease Innovation at Ropes & Gray’s Annual Forum
17
0/100